The Experts below are selected from a list of 468 Experts worldwide ranked by ideXlab platform
Georgwilhelm Bornkamm - One of the best experts on this subject based on the ideXlab platform.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
Klaus Felix - One of the best experts on this subject based on the ideXlab platform.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
Thomas Ried - One of the best experts on this subject based on the ideXlab platform.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
Gary M Jones - One of the best experts on this subject based on the ideXlab platform.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
S S Park - One of the best experts on this subject based on the ideXlab platform.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.
-
inducible mutagenesis in tepc 2372 a mouse Plasmacytoma Cell Line that harbors the transgenic shuttle vector λliz
Mutation Research, 2001Co-Authors: Klaus Felix, Alexander L Kovalchuk, Allen E Coleman, E S Ramsay, M Qian, Kevin Kelliher, Gary M Jones, Thomas Ried, S S Park, Georgwilhelm BornkammAbstract:Abstract The Plasmacytoma Cell Line, TEPC 2372, was derived from a malignant plasma Cell tumor that developed in the peritoneal cavity of a BALB/c mouse that harbored the transgenic shuttle vector for the assessment of mutagenesis in vivo, λLIZ. TEPC 2372 was found to display the typical features of a BALB/c Plasmacytoma. It consisted of pleomorphic plasma Cells that secreted a monoclonal immunoglobulin (IgG2b/λ), was initially dependent on the presence of IL-6 to grow in Cell culture, contained a hyperdiploid chromosome complement with a tendency to undergo tetraploidization, and harbored a constitutively active c- myc gene by virtue of a T(6;15) chromosomal translocation. TEPC 2372 was further characterized by the ability to respond to in vitro exposure with 4-NQO (4-nitroquinoLine-1-oxide), an oxidative model mutagen, with a vigorous dose-dependent increase in mutagenesis that peaked at a 7.85-fold elevation of mutant rates in λLIZ when compared to background mutant rates in untreated controls. Cotreatment with 4-NQO and BSO (buthionine sulfoximine), a glutathione-depleting compound that causes endogenous oxidative stress, resulted in a 9.03-fold increase in the mutant frequency in λLIZ. These results demonstrated that TEPC 2372, the malignant plasma Cell counterpart of the λLIZ-based in vivo mutagenesis assay, may be useful as an in vitro reference point for the further elucidation of oxidative mutagenesis in lymphoid tissues.